Skip to main content

Search

Clear
Filter by Type
Filter by Topics
Filter by Symptoms & Conditions
Filter by Year
Advocacy in Action: Fee Schedule Comment Letters From APTA Members, Part 1

Aug 23, 2022/Perspective

We're sharing real-world examples of what makes for a great comment letter. This installment: a new PT's perspective.

APTA 2022 State Legislation Roundup: Prior Authorization, Telehealth, and More

Aug 26, 2022/Roundup

State advocates for the profession racked up some important wins this year. Here are highlights.

Commercial Payer Update, August 2022

Aug 24, 2022/Roundup

The PTA differential, MPPR, payment limits, and more.

APTA Consumer Awareness Report Shows Deepening Knowledge of Physical Therapy

Sep 27, 2022/News

Based on a 2021 survey, the results show significant growth in the public's understanding of the profession's role and level of expertise.

Coronavirus Update: September 30

Sep 30, 2022/Roundup

APTA Long COVID course, neurologic disorders risk, relaxed CDC guidelines, new virus found in bats, and more.

APTA Monkeypox Practice Advisory Now Available

Oct 3, 2022/News

The new resource is a quick reference to help PTs, PTAs, and others reduce the risk of transmission in clinical settings.

Be Humble, Curious, and Ready to Learn: Care for the Native American Population

Oct 8, 2022/News

APTA Magazine connects with experienced providers to explore keys to providing culturally competent physical therapy.

New Report: Outpatient Practices Faced 'Significant' Employee Vacancy Rates

Sep 21, 2022/News

In a midyear survey most owners cited relocation, pay, and work-life balance as the main reasons behind employee loss.

Researchers: Studies Show Telehealth to Be 'Feasible and Effective' in Rehab

Sep 19, 2022/Review

A systematic review involving more than 200,000 patients with a variety of conditions revealed consistently positive results for telerehab.

APTA Advocacy Win: Bill to Address Prior Authorization One Step Closer to Law

Sep 16, 2022/News

Legislation that takes aim at prior authorization under Medicare Advantage has passed the House and is moving on for Senate approval.